Algorithmic Computation of Combined LT4 Plus LT3 Replacement Therapies for Primary Hypothyroid Patients Individualized by Sex, Height, and Weight
Thyroid® · 18.11.2026
DOI: 10.1177/10507256261502926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, online erschienen am 18.11.2026. Verfasst von Katarina Reid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biocybernetics Laboratory, UCLA, Los Angeles, California, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Fred Ebrahimi Foundation, for publication charges.
Abstract (Originalsprache)
Background/Methods: Levothyroxine (LT4) monotherapy fails to fully normalize thyroid hormone levels or relieve symptoms in 10–20% of hypothyroid patients, prompting interest in combination therapy with added liothyronine (LT3). Existing dosing guidance is largely qualitative. Using the p-THYROSIM mechanistic model—previously fitted and validated against data from 655 patients—we developed computational algorithms from ∼400 simulations to generate individualized residual thyroid function (RTF) values and combination LT4/LT3 dosing recommendations based on a patient’s sex, height ( H ), weight ( W ), and measured hormone values [TSH, free thyroxine (fT4), and free triiodothyronine (fT3) or total T3 (TT3)]. We implemented these in a user-friendly clinical software package as an app called LT43DOSING.
Results
Simulated temporal plots of fT4, fT3, and TSH for combined dosages in available pill sizes are computed and reported as outputs of LT43DOSING, along with RTFs, separately for both sexes, with body mass indexes (BMIs) ranging from ∼15 to 40. Computed RTFs and dosages are based on patient H , W , and serum hormone concentrations provided as input data. Our findings show that both W and H affect dosing in a nonlinear manner, especially at BMI extremes, whereas sex made little difference. Only combination therapy was able to normalize fT3 levels.
Conclusions
In simulated identical BMI patients, different H and W combinations produced markedly different RTF values, leading to more accurate dosing predictions based on body size. Simulated combination therapy normalized fT3 levels whereas monotherapy did not, particularly for overtly hypothyroid patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biocybernetics Laboratory, UCLA, Los Angeles, California, USA.
- Division of Endocrinology, Department of Medicine, UCLA, Los Angeles, California, USA.
- Department of Computer Science and Department of Medicine, UCLA, Los Angeles, California, USA.
ORCID-Profile: Katarina Reid, Kasra Navabi, Joseph DiStefano
Förderung
- The Fred Ebrahimi Foundation, for publication charges
Zitieren
APA
Reid, K., Navabi, K., Shah, R., & DiStefano, J. (2026). Algorithmic Computation of Combined LT4 Plus LT3 Replacement Therapies for Primary Hypothyroid Patients Individualized by Sex, Height, and Weight. Thyroid®. https://doi.org/10.1177/10507256261502926
Vancouver
Reid K, Navabi K, Shah R, DiStefano J. Algorithmic Computation of Combined LT4 Plus LT3 Replacement Therapies for Primary Hypothyroid Patients Individualized by Sex, Height, and Weight. Thyroid®. 2026. doi:10.1177/10507256261502926
BibTeX
@article{Reid2026,
author = {Reid, Katarina and Navabi, Kasra and Shah, Rushil and DiStefano, Joseph},
title = {Algorithmic Computation of Combined LT4 Plus LT3 Replacement Therapies for Primary Hypothyroid Patients Individualized by Sex, Height, and Weight},
journal = {Thyroid®},
year = {2026},
doi = {10.1177/10507256261502926}
}
EUVIMED